Skip to main content

Elopag 20 mg ( Eltrombopag)

What Is Elopag?

Elopag is a brand name associated with eltrombopag, a prescription medicine used to increase platelet production in certain patients with low platelet counts. It belongs to a class of medicines called thrombopoietin receptor agonists (TPO-RAs).

Eltrombopag works by stimulating thrombopoietin receptors in the bone marrow. This encourages the development and maturation of megakaryocytes, which are large cells responsible for producing platelets.

Platelets are essential components of blood that help control bleeding and support normal blood clotting. When platelet levels become too low, a person may experience easy bruising, bleeding gums, nosebleeds or other bleeding complications.

Elopag may be prescribed for selected patients with persistent or chronic immune thrombocytopenia (ITP), certain cases of chronic hepatitis C-associated thrombocytopenia and severe aplastic anaemia, depending on the applicable product approval and treatment guidelines.

Eltrombopag is a specialist prescription medicine. Its use requires appropriate patient assessment, platelet-count monitoring and liver-function monitoring.

Product strength clarification: Everest Pharmaceuticals’ official catalogue lists Elopag 25 mg and Elopag 50 mg. The specific Elopag 20 mg strength has not been confirmed in that catalogue. Confirm the actual product strength and manufacturer against the original packaging before publishing a 20 mg product claim.

Medicine Overview

InformationDetails
Brand nameElopag
Active ingredientEltrombopag
Medicine classThrombopoietin receptor agonist
Therapeutic categoryHaematology
Main functionStimulates platelet production
AdministrationOral
Common reference-product dosage formsTablets and oral suspension
Prescription statusPrescription medicine
Main treatment areasITP, selected hepatitis C-associated thrombocytopenia and severe aplastic anaemia
Officially listed Everest Elopag strengths25 mg and 50 mg

What Is the Active Ingredient in Elopag?

The active ingredient in Elopag is eltrombopag. Pharmaceutical reference products commonly contain eltrombopag olamine, with the stated strength expressed as an equivalent amount of eltrombopag.

Eltrombopag is designed to activate the thrombopoietin receptor, which plays an important role in platelet production.

Unlike platelet transfusions, which provide platelets directly, eltrombopag stimulates the body’s own bone marrow to produce additional platelets.

The medicine is used in specific conditions where increasing platelet production may help reduce bleeding risk or support the management of an underlying blood disorder.

How Does Elopag Work?

Elopag works by stimulating thrombopoietin receptors located on bone marrow cells involved in platelet development.

The mechanism involves several important stages:

1. Thrombopoietin receptor stimulation

Eltrombopag interacts with the thrombopoietin receptor, also known as c-Mpl, on bone marrow cells.

2. Activation of cell-signalling pathways

The medicine stimulates intracellular signalling pathways involved in the growth and development of platelet-producing cells.

3. Megakaryocyte development

These signals encourage the development and maturation of megakaryocytes in the bone marrow.

4. Increased platelet production

Mature megakaryocytes release platelets into the bloodstream.

5. Improved platelet count

As platelet production increases, the circulating platelet count may rise. This can help reduce bleeding risk in appropriately selected patients.

The treatment response differs between individuals. The aim is generally to achieve a platelet count sufficient to reduce bleeding risk rather than to normalise platelet levels unnecessarily.

What Is Elopag Used For?

Eltrombopag is used for certain medical conditions associated with low platelet counts or impaired blood-cell production.

Its established reference-product uses include:

  • Persistent or chronic immune thrombocytopenia (ITP) in eligible patients.
  • Thrombocytopenia associated with chronic hepatitis C in specified treatment settings.
  • Severe aplastic anaemia in approved treatment settings.

The exact approved indications, age restrictions and treatment combinations depend on the country’s regulatory approval and the product’s official prescribing information.

Benefits of Elopag

When prescribed for an appropriate condition, eltrombopag may offer several potential treatment benefits.

Supports Platelet Production

Eltrombopag stimulates the thrombopoietin receptor in the bone marrow, helping the body produce more platelets.

May Reduce Bleeding Risk

In selected patients with thrombocytopenia, increasing platelet counts may help reduce the risk of bleeding complications.

Oral Treatment Option

Eltrombopag is available in oral formulations, allowing patients to take the medicine by mouth rather than receiving it as a platelet transfusion.

Supports Treatment of Selected Blood Disorders

It provides an additional treatment option for eligible patients with persistent or chronic ITP and certain other approved conditions.

Allows Treatment Monitoring

Doctors can assess platelet-count changes and adjust treatment according to the patient’s response and safety results.

These benefits are not guaranteed for every patient. Treatment effectiveness depends on the underlying condition, individual response and appropriate medical management.

Dosage and Strength Information

Eltrombopag is available in different strengths depending on the manufacturer and market.

The correct dose is determined by the treating healthcare professional according to:

  • The condition being treated.
  • The patient’s age.
  • Platelet-count response.
  • Liver function.
  • Medical history.
  • Other medicines being taken.
  • The applicable prescribing instructions.

For example, U.S. reference-product dosing differs between ITP, chronic hepatitis C-associated thrombocytopenia and severe aplastic anaemia.

A 20 mg tablet should not automatically be considered the standard daily dose. The strength of an individual tablet and the prescribed daily dose are not necessarily the same.

Important: Do not select or adjust an eltrombopag dose independently. Follow the exact prescription and product-specific instructions.

How to Take Elopag

Eltrombopag is administered orally according to the prescribed treatment schedule.

General administration considerations include:

  • Take the medicine exactly as prescribed.
  • Follow a consistent daily schedule when prescribed once daily.
  • Follow the instructions regarding food and calcium intake.
  • Separate the medicine from calcium-rich foods and relevant mineral-containing products.
  • Do not take an additional dose to compensate for a missed dose.
  • Attend scheduled blood tests.

Reference-product instructions recommend taking eltrombopag without food or with a meal containing no more than 50 mg of calcium.

It should generally be taken at least 2 hours before or 4 hours after products containing polyvalent cations, including calcium, iron, magnesium, aluminium, zinc and selenium.

Follow the instructions provided with the actual product and consult a pharmacist if you are unsure about medicine timing.

Possible Side Effects of Elopag

Like other prescription medicines, eltrombopag may cause adverse reactions. Some patients experience mild symptoms, while others may develop more serious complications.

Commonly reported reactions across the approved treatment indications include:

  • Nausea.
  • Diarrhoea.
  • Headache.
  • Fatigue.
  • Cough.
  • Fever.
  • Anaemia.
  • Increased liver enzymes.

Important serious risks include:

Liver toxicity: Eltrombopag may cause liver injury. Liver-function monitoring is necessary.

Blood clots: Thrombotic and thromboembolic events have been reported, including portal vein thrombosis in patients with chronic liver disease.

Hepatic complications: Patients with chronic hepatitis C receiving eltrombopag with interferon and ribavirin may have an increased risk of hepatic decompensation.

Cataracts: Cataracts have been reported during treatment.

Patients should report unusual symptoms to their healthcare professional and seek urgent attention for chest pain, breathing difficulty, stroke-like symptoms, severe abdominal pain or significant bleeding.

Important Precautions Before Using Elopag

Before starting treatment, patients should discuss their medical history with their doctor.

Important considerations include:

  • Existing liver disease.
  • Previous blood clots.
  • Cardiovascular or circulation problems.
  • Previous cataracts or other eye conditions.
  • Pregnancy or breastfeeding.
  • Other blood or bone marrow disorders.
  • Current prescription medicines and supplements.

Regular platelet-count and liver-function monitoring is important during treatment.

Eltrombopag should not be used as a general treatment for every cause of low platelet counts. The underlying diagnosis must be established by a qualified healthcare professional.

Storage and Handling

Store Elopag according to the instructions printed on the original product packaging.

General medicine-handling precautions include:

  • Keep the medicine in its original packaging.
  • Protect it from unsuitable storage conditions.
  • Avoid exposure to excessive heat or moisture.
  • Keep it away from children.
  • Do not use tablets after their expiry date.
  • Ask a pharmacist how to dispose of unused or expired medicine.

Always follow the manufacturer’s specific storage instructions.

Who Should Use Elopag?

Eltrombopag may be appropriate for patients who meet the approved treatment criteria for certain blood disorders.

The treating specialist considers the diagnosis, platelet count, previous treatment response, liver function and other medical factors before prescribing it.

Patients should not use Elopag simply because they have a low platelet count. Different causes of thrombocytopenia require different treatment approaches.

Frequently Asked Questions About Elopag

1. What is Elopag?

Elopag is a brand name associated with eltrombopag, a prescription medicine that stimulates platelet production in the bone marrow.

2. What is the active ingredient in Elopag?

The active ingredient is eltrombopag, a thrombopoietin receptor agonist.

3. What is Elopag used for?

Eltrombopag is used in selected patients with persistent or chronic immune thrombocytopenia, chronic hepatitis C-associated thrombocytopenia in specified settings and severe aplastic anaemia.

4. How does Elopag work?

It stimulates thrombopoietin receptors in the bone marrow, encouraging megakaryocyte development and increasing platelet production.

5. Is Elopag a chemotherapy medicine?

No. Eltrombopag is a thrombopoietin receptor agonist. It is not classified as conventional chemotherapy.

6. Does Elopag increase platelet counts?

Yes. Eltrombopag stimulates platelet production and may increase platelet counts in patients who respond to treatment.

7. Is Elopag available as an oral medicine?

Yes. Eltrombopag is available in oral formulations, including tablets and oral suspension in reference products.

8. Can Elopag be taken without food?

Reference-product instructions recommend taking eltrombopag without food or with a meal low in calcium. Follow the instructions for the specific product.

9. Does Elopag require regular blood tests?

Yes. Platelet counts and liver-function tests are important parts of treatment monitoring.

10. Can everyone with low platelets take Elopag?

No. Eltrombopag is approved for specific conditions and requires specialist assessment. It is not suitable for every cause of thrombocytopenia.

Medical Disclaimer

This page provides general educational information about Elopag and its active ingredient, eltrombopag. It is not a substitute for professional medical advice, diagnosis or treatment. Eltrombopag should only be used under the supervision of a qualified healthcare professional. Always follow the approved product information and your doctor’s instructions.

Product verification notice: Everest Pharmaceuticals’ official catalogue lists Elopag 25 mg and Elopag 50 mg. The specific Elopag 20 mg strength has not been verified in that catalogue. Confirm the product’s actual strength, formulation, manufacturer and regulatory status against official documentation before publication.